MAP Pharmaceuticals, Inc. announced today that its Unit Dose Budesonide (UDB) drug candidate met its primary efficacy endpoints in a Phase 2 clinical trial. UDB is a proprietary nebulized formulation of budesonide for treatment of pediatric asthma. The multicenter, randomized, double-blind, placebo-controlled U.S. based study aimed to assess the efficacy of UDB versus placebo at two doses in patients as young as 12-months old. [click link for full article]
(more...)